Search Results - "Ruëff, F"

Clinical contraindications to allergen immunotherapy: an EAACI position paper by Pitsios, C., Demoly, P., Bilò, M. B., Gerth van Wijk, R., Pfaar, O., Sturm, G. J., Rodriguez del Rio, P., Tsoumani, M., Gawlik, R., Paraskevopoulos, G., Ruëff, F., Valovirta, E., Papadopoulos, N. G., Calderón, M. A.

“…Clinical indications for allergen immunotherapy (AIT) in respiratory and Hymenoptera venom allergy are well established; however, clinical contraindications to…”
Get full text

H1‐antihistamine‐refractory chronic spontaneous urticaria: it's worse than we thought – first results of the multicenter real‐life AWARE study by Maurer, M., Staubach, P., Raap, U., Richter‐Huhn, G., Bauer, A., Ruëff, F., Jakob, T., Yazdi, A. S., Mahler, V., Wagner, N., Lippert, U., Hillen, U., Schwinn, A., Pawlak, M., Behnke, N., Chaouche, K., Chapman‐Rothe, N.

“…Summary Background Most data on chronic spontaneous urticaria (CSU) originate from highly selected patient populations treated at specialized centres. Little…”
Get full text

EAACI guidelines on allergen immunotherapy: Hymenoptera venom allergy by Sturm, G. J., Varga, E.‐M., Roberts, G., Mosbech, H., Bilò, M. B., Akdis, C. A., Antolín‐Amérigo, D., Cichocka‐Jarosz, E., Gawlik, R., Jakob, T., Kosnik, M., Lange, J., Mingomataj, E., Mitsias, D. I., Ollert, M., Oude Elberink, J. N. G., Pfaar, O., Pitsios, C., Pravettoni, V., Ruëff, F., Sin, B. A., Agache, I., Angier, E., Arasi, S., Calderón, M. A., Fernandez‐Rivas, M., Halken, S., Jutel, M., Lau, S., Pajno, G. B., Ree, R., Ryan, D., Spranger, O., Wijk, R. G., Dhami, S., Zaman, H., Sheikh, A., Muraro, A.

“…Hymenoptera venom allergy is a potentially life‐threatening allergic reaction following a honeybee, vespid, or ant sting. Systemic‐allergic sting reactions…”
Get full text

Predictors of clinical effectiveness of Hymenoptera venom immunotherapy by Ruëff, F., Vos, B., Oude Elberink, J., Bender, A., Chatelain, R., Dugas-Breit, S., Horny, H.-P., Küchenhoff, H., Linhardt, A., Mastnik, S., Sotlar, K., Stretz, E., Vollrath, R., Przybilla, B., Flaig, M.

“…Summary Background Treatment failure during venom immunotherapy (VIT) may be associated with a variety of risk factors, of which the relative importance is…”
Get full text

Factors increasing the risk for a severe reaction in anaphylaxis: An analysis of data from The European Anaphylaxis Registry by Worm, M., Francuzik, W., Renaudin, J.‐M., Bilo, M. B., Cardona, V., Scherer Hofmeier, K., Köhli, A., Bauer, A., Christoff, G., Cichocka‐Jarosz, E., Hawranek, T., Hourihane, J. O.’B., Lange, L., Mahler, V., Muraro, A., Papadopoulos, N. G., Pföhler, C., Poziomkowska‐Gęsicka, I., Ruëff, F., Spindler, T., Treudler, R., Fernandez‐Rivas, M., Dölle, S.

“…Background Preventive measures to decrease the frequency and intensity of anaphylactic events are essential to provide optimal care for allergic patients…”
Get full text

Overcoming severe adverse reactions to venom immunotherapy using anti‐IgE antibodies in combination with a high maintenance dose by Stretz, E., Oppel, E. M., Räwer, H.‐C., Chatelain, R., Mastnik, S., Przybilla, B., Ruëff, F.

“…Summary Background An omalizumab treatment and a high maintenance venom dose may both help to prevent recurrent systemic allergic reactions (SAR) to venom…”
Get full text

Symptom profile and risk factors of anaphylaxis in Central Europe by Worm, M., Edenharter, G., Ruëff, F., Scherer, K., Pföhler, C., Mahler, V., Treudler, R., Lang, R., Nemat, K., Koehli, A., Niggemann, B., Hompes, S.

“…Background Anaphylaxis is the most severe manifestation of an IgE‐dependent allergy. Standardized acquired clinical data from large cohorts of well‐defined…”
Get full text

Occupational anaphylaxis – an EAACI task force consensus statement by Siracusa, A., Folletti, I., Gerth van Wijk, R., Jeebhay, M. F., Moscato, G., Quirce, S., Raulf, M., Ruëff, F., Walusiak‐Skorupa, J., Whitaker, P., Tarlo, S. M.

“…Anaphylaxis is a systemic allergic reaction, potentially life‐threatening that can be due to nonoccupational or, less commonly, to occupational triggers…”
Get full text

BASALIT trial: double‐blind placebo‐controlled allergen immunotherapy with rBet v 1‐FV in birch‐related soya allergy by Treudler, R., Franke, A., Schmiedeknecht, A., Ballmer‐Weber, B., Worm, M., Werfel, T., Jappe, U., Biedermann, T., Schmitt, J., Brehler, R., Kleinheinz, A., Kleine‐Tebbe, J., Brüning, H., Ruëff, F., Ring, J., Saloga, J., Schäkel, K., Holzhauser, T., Vieths, S., Simon, J. C.

“…Background Conflicting results exist on the effect of allergen immunotherapy (AIT) on pollen‐related food allergy. We aimed to investigate the efficacy of…”
Get full text

A new basophil activation test using CD63 and CCR3 in allergy to antibiotics by Eberlein, B., Suárez, I. León, Darsow, U., Ruëff, F., Behrendt, H., Ring, J.

“…Summary Background Flow cytometric basophil activation tests (BAT) have been developed as cellular tests for in vitro diagnosis of IgE‐mediated reactions…”
Get full text

Contraindications to immunotherapy: a global approach by Pitsios, C., Tsoumani, M., Bilò, M. B., Sturm, G. J., Rodríguez del Río, P., Gawlik, R., Ruëff, F., Paraskevopoulos, G., Valovirta, E., Pfaar, O., Calderón, M. A., Demoly, P.

“…Background Recommendations on contraindications to allergen immunotherapy (AIT) have been independently developed by National and International…”
Get full text

Meat allergy associated with galactosyl‐α‐(1,3)‐galactose (α‐Gal)—Closing diagnostic gaps by anti‐α‐Gal IgE immune profiling by Jappe, U., Minge, S., Kreft, B., Ludwig, A., Przybilla, B., Walker, A., Varga, R., Seidel, P., Biedermann, T., Anemüller, W., Kromminga, A., Ruëff, F., Merk, H., Wagner, N., Treudler, R., Worm, M., Waldmann, I., Saloga, J., Becker, W. M., Goldmann, T., Platts‐Mills, T. A., Homann, A.

“…Background Glycoproteins and glycolipids of some mammalian species contain the disaccharide galactosyl‐α‐(1,3)‐galactose (α‐Gal). It is known that α‐Gal is…”
Get full text

Patients still reacting to a sting challenge while receiving conventional Hymenoptera venom immunotherapy are protected by increased venom doses by Ruëff, Franziska, Wenderoth, Andrea, Przybilla, Bernhard

“…Background: Up to 20% of patients allergic to Hymenoptera venom are not protected by conventional venom immunotherapy (VIT) with 100 μg of any single venom…”
Get full text

Serum concentration of baseline mast cell tryptase: evidence for a decline during long-term immunotherapy for Hymenoptera venom allergy by Dugas-Breit, S., Przybilla, B., Dugas, M., Arnold, A., Pfundstein, G., Küchenhoff, H., Ruëff, F.

“…Summary Background Baseline serum mast cell tryptase concentration (BTC) is thought to reflect the constitutive mast cell load or activity of an individual…”
Get full text

Fatal anaphylactic sting reaction in a patient with mastocytosis by Wagner, N, Fritze, D, Przybilla, B, Hagedorn, M, Ruëff, F

“…We report on a 33-year-old female patient with indolent systemic mastocytosis and urticaria pigmentosa who died of an anaphylactic reaction after a yellow…”
Get more information

Photoallergic contact dermatitis due to treatment of pulmonary fibrosis with pirfenidone by Reinholz, M., Eder, I., Przybilla, B., Schauber, J., Wollenberg, A., Wulffen, W., Goldscheider, I., Varga, R., Ruzicka, T., Schaumann, A., Ruëff, F.

Get full text

Standardization of double blind placebo controlled food challenge with soy within a multicentre trial by Treudler, R., Franke, A., Schmiedeknecht, A., Ballmer‐Weber, B. K., Worm, M., Werfel, T., Jappe, U., Biedermann, T., Schmitt, J., Brehler, R., Kleinheinz, A., Kleine‐Tebbe, J., Brüning, H., Ruëff, F., Ring, J., Saloga, J., Schäkel, K., Holzhauser, T., Vieths, St, Simon, J. C.

“…Background Multicentre trials investigating food allergies by double blind placebo controlled food challenges (DBPCFC) need standardized procedures, challenge…”
Get full text

Anaphylaxis: guidelines from the European Academy of Allergy and Clinical Immunology by Muraro, A., Roberts, G., Worm, M., Bilò, M. B., Brockow, K., Fernández Rivas, M., Santos, A. F., Zolkipli, Z. Q., Bellou, A., Beyer, K., Bindslev‐Jensen, C., Cardona, V., Clark, A. T., Demoly, P., Dubois, A. E. J., DunnGalvin, A., Eigenmann, P., Halken, S., Harada, L., Lack, G., Jutel, M., Niggemann, B., Ruëff, F., Timmermans, F., Vlieg–Boerstra, B. J., Werfel, T., Dhami, S., Panesar, S., Akdis, C. A., Sheikh, A.

“…Anaphylaxis is a clinical emergency, and all healthcare professionals should be familiar with its recognition and acute and ongoing management. These…”
Get full text

Immunotherapy for Hymenoptera venom allergy: too expensive for European health care? by Ruëff, F., Biló, M. B., Cichocka‐Jarosz, E., Müller, U., Elberink, H. Oude, Sturm, G.

Get full text

Specific immunotherapy in honeybee venom allergy: a comparative study using aqueous and aluminium hydroxide adsorbed preparations by Ruëff, F., Wolf, H., Schnitker, J., Ring, J., Przybilla, B.

“…Background:  For the immunotherapy of Hymenoptera venom allergy various preparations and treatment protocols are in use. However, controlled studies making…”
Get full text